Edition:
United States

D Pharm Ltd (DPRM.TA)

DPRM.TA on Tel Aviv Stock Exchange

94.20ILa
23 Apr 2017
Change (% chg)

-- (--)
Prev Close
94.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,816
52-wk High
225.00
52-wk Low
60.00

Latest Key Developments (Source: Significant Developments)

D Pharm Ltd receives final positive results from a pilot Phase 2 study
Thursday, 30 Jul 2015 08:00am EDT 

D Pharm Ltd:Receives final positive results from a pilot Phase 2 study.Clinical study exploring DP-b99 in patients with acute high-risk inflammation of the pancreas.Preclinical and clinical data indicate a favorable safety profile for DP-b99.  Full Article

D Pharm Ltd receives final report for its phase 2 clinical study of THR-18 in acute stroke patients treated with tPA
Thursday, 14 May 2015 07:00am EDT 

D Pharm Ltd:Has received final report for its Phase 2 clinical study of THR-18.Says THR-18 demonstrated statistically significant reductions in the incidence of intracranial hemorrhage (ICH), brain swelling (edema) and a satisfactory safety profile in stroke patients treated with tPA.Moreover, stroke recovery was improved 2-fold in patients receiving THR-18, as judged by clinical outcome measures, 30 days following stroke.study successfully defined the maximal tolerated and safe dose of THR-18 in AIS patients.Imaging data as assessed by CT (computed tomography) on day 2 following stroke and tPA treatment indicate that, in contrast to placebo group, no patients treated with THR-18 had an intracranial hemorrhage, (p=0.02).Similarly, 0.54 mg/kg of THR-18 reduced by more than twice the occurrence of brain edema (p<0.05).  Full Article

More From Around the Web

No consensus analysis data available.